MedTrace Logo

A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)

NCT00142558 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2024-08-15

No results posted yet for this study

Summary

A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute gout.

Conditions

  • Acute Gout

Interventions

DRUG

MK0663; etoricoxib / Duration of Treatment: 5 Days

DRUG

Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-01
Primary Completion
2005-05-01
Completion
2005-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00142558 on ClinicalTrials.gov